Date:2021/12/04
Your Name:Zihao Zhou
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007) the Science and Technology Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	None	
В	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

**Zihao Zhou** reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007), and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Shujie Huang
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007) the Science and Technology Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04	
Your Name: Xiaosong Ben	
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could	
penefit from adjuvant chemotherapy	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007) the Science and Technology Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cumpart for attanding	Nene	
/	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Weitao Zhuang
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
penefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g., funding,	the 2020-2021 Popularization of Science and Technology	
	provision of study materials,	Innovation Special Project of	
	medical writing, article processing charges, etc.)	Guangdong Province of China (No. 2020A1414070007)	
	No time limit for this item.	the Science and Technology	
		Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	None	
В	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
	meetings and, or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
4.0	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Liangli Hong
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
penefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution) g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007)  the Science and Technology Program of Guangzhou, China (201704020107)	
2	Grants or contracts from any entity (if not indicated	Time frame: past 36 mon	ths
3	in item #1 above).  Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	inone	
	o ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	Notice	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Zefeng Xie
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No.	
	processing charges, etc.)	2020A1414070007)	
	No time limit for this item.	the Science and Technology Program of Guangzhou, China (201704020107)  Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
	_		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	None	
В	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
	meetings and, or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	-	None	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Dongkun Zhang
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients cou
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plannin	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007)  the Science and Technology Program of Guangzhou, China (201704020107)	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
_		N	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel	Helic	
8	Patents planned, issued or	None	
	pending		
	Deuticination on a Data	News	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
-1	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Liang Xie
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution) g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007)  the Science and Technology Program of Guangzhou, China (201704020107)	
2	Grants or contracts from any entity (if not indicated	Time frame: past 36 mon	ths
3	in item #1 above).  Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
_			
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	Hone	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

# Please place an "X" next to the following statement to indicate your agreement:

ate:2021/12/04
our Name:Haiyu Zhou
lanuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
enefit from adjuvant chemotherapy
lanuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g., funding,	the 2020-2021 Popularization of Science and Technology	
	provision of study materials,	Innovation Special Project of	
	medical writing, article processing charges, etc.)	Guangdong Province of China (No. 2020A1414070007)	
	No time limit for this item.	the Science and Technology	
		Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cumpart for attanding	Nene	
/	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/12/04 2021/12/04				
Your Name:Jiming Tang				
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could				
benefit from adjuvant chemotherapy				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution) g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007)  the Science and Technology Program of Guangzhou, China (201704020107)	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	ths
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10		Name	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	None	
	andar meer coto		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Gang Chen
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		<u> </u>	<u> </u>
		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g., funding,	the 2020-2021 Popularization of Science and Technology	
	provision of study materials,	Innovation Special Project of	
	medical writing, article processing charges, etc.)	Guangdong Province of China (No. 2020A1414070007)	
	No time limit for this item.	the Science and Technology	
		Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
_	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0		Notice	
	testimony		
_			
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending	None	
	periumg		
0	Double in the control of the	News	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	110.110	
	illianciai iliterests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04
Your Name:Hansheng Wu
Manuscript Title: A novel prognostic model: which group of esophageal squamous cell carcinoma patients could
benefit from adjuvant chemotherapy
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution) ag of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007) the Science and Technology Program of Guangzhou, China (201704020107)	
		Time frame: past 36 mon	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	inone	
	o ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	Notice	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/12/04				
Your Name:Guibin Qiao				
ll carcinoma patients could benefit from adjuvant chemotherapy				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your		
		none (add rows as needed)	institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007) the Science and Technology Program of Guangzhou, China (201704020107)			
		Time frame: past 36 mon	ths		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None			

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
15	financial interests		

The author reports that this work was supported by a grant from the 2020-2021 Popularization of Science and Technology Innovation Special Project of Guangdong Province of China (No. 2020A1414070007); and the Science and Technology Program of Guangzhou, China (201704020107).

### Please place an "X" next to the following statement to indicate your agreement: